Chronic Treatment With Serelaxin Mitigates Adverse Remodeling in a Murine Model of Ischemic Heart Failure and Modulates Bioactive Sphingolipid Signaling
Researchers examined the effects of relaxin on sphingosine 1-phosphate, and the potential benefits of relaxin treatment on cardiac health in a rodent model of ischemic heart failure.